Abstract
Objective: In the United Kingdom many genitourinary medicine clinics use oral doxycycline and metronidazole to treat pelvic inflammatory disease (PID). A retrospective case note review of PID treatment at our department in 2000 showed that the clinical cure rate (CCR) was only 55% with oral doxycycline and metronidazole for 2 weeks. We therefore added ceftriaxone 250 mg intramuscularly to the doxycycline and metronidazole for treating PID. We have repeated the review and compared the results with those from 2000.
Methods: All patients diagnosed as having PID between 1 July 2002 and 31 December 2002 were identified. These episodes were diagnosed on clinical presentations of pelvic pain, vaginal discharge or bleeding, and cervical motion tenderness on physical examination. The CCR was defined as patients who fully resolved their symptoms and signs during 2 week and 4 week follow up. The results were compared with those from 2000.
Results: Women receiving ceftriaxone, doxycycline, and metronidazole had a CCR of 72%. In 2000 the CCR for women receiving only doxycycline and metronidazole was 55%. There were only 8% non-responders in 2002 compared with 18% in 2000. Comparing CCR and non-response rate, in 2002 there was a significant improvement in cure rate, OR 3.01 (95% CI 1.28 to 7.47) p = 0.009. Using an intent to treat analysis and including the defaulters as treatment failures there was still a significant improvement in cure rate, OR 2.03 (95% CI 1.18 to 3.50) p = 0.009.
Conclusions: The treatment of PID with ceftriaxone, doxycycline, and metronidazole gave a significantly higher CCR than doxycycline and metronidazole. Our experience would suggest that doxycycline and metronidazole alone is not a suitable regimen for treatment of PID in the United Kingdom.
Full Text
The Full Text of this article is available as a PDF (51.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arredondo J. L., Diaz V., Gaitan H., Maradiegue E., Oyarzún E., Paz R., Reynal J. L., Stamm W., Zambrano D. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis. 1997 Feb;24(2):170–178. doi: 10.1093/clinids/24.2.170. [DOI] [PubMed] [Google Scholar]
- National guideline for the management of pelvic infection and perihepatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect. 1999 Aug;75 (Suppl 1):S54–S56. [PubMed] [Google Scholar]
- Ness Roberta B., Soper David E., Holley Robert L., Peipert Jeffrey, Randall Hugh, Sweet Richard L., Sondheimer Steven J., Hendrix Susan L., Amortegui Antonio, Trucco Giuliana. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol. 2002 May;186(5):929–937. doi: 10.1067/mob.2002.121625. [DOI] [PubMed] [Google Scholar]
- Piyadigamage Anura, Wilson Janet D. An audit of outpatient management of pelvic inflammatory disease. Int J STD AIDS. 2002 Aug;13(8):577–579. doi: 10.1258/095646202760159738. [DOI] [PubMed] [Google Scholar]
- Ross J. Pelvic inflammatory disease. BMJ. 2001 Mar 17;322(7287):658–659. doi: 10.1136/bmj.322.7287.658. [DOI] [PMC free article] [PubMed] [Google Scholar]